Literature DB >> 2743269

Adrenal cortical carcinoma.

S Venkatesh1, R C Hickey, R V Sellin, J F Fernandez, N A Samaan.   

Abstract

The records of 110 patients (58 females and 52 males) with histologically proven adrenal cortical carcinoma were studied. Fifty-six of 110 (50.9%) patients had abdominal symptoms and 33 (30.0%) had a palpable abdominal mass. Surgery for localized and regional disease was associated with a disease-free survival time of at least 2 years in 28 of the 50 (56%) patients. Abdominal radiotherapy, systemic chemotherapy, and 1,1 dichloro-2 (O-chlorophenyl)-2 (P-chlorophenyl) ethane (OPDDD) were effective in three of 19 (15.8%) patients, three of 31 (9.7%) patients, and 21 of 72 (29.2%) patients, respectively. Combined radiotherapy and OPDDD did not confer any additional benefit over OPDDD alone. Six of seven patients who received OPDDD as adjuvant treatment are still alive at 1 to 4 years. Distant metastases occurred most commonly in the lungs, liver, peritoneum, lymph nodes, and bones. Only 23% of the patients survived 5 years or more. We conclude that early diagnosis and complete surgical excision offer the best prospects for long-term survival and that the efficacy of adjuvant OPDDD needs to be evaluated further.

Entities:  

Mesh:

Year:  1989        PMID: 2743269     DOI: 10.1002/1097-0142(19890801)64:3<765::aid-cncr2820640333>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

Review 1.  Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

Authors:  E Baudin; S Leboulleux; A Al Ghuzlan; C Chougnet; J Young; D Deandreis; F Dumont; F Dechamps; C Caramella; P Chanson; E Lanoy; I Borget; M Schlumberger
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

2.  Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases.

Authors:  Osamu Imataki; Atsushi Makimoto; Rie Kojima; Michiyo Sakiyama; Ako Hosono; Yoichi Takaue
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

3.  Actual 10-year survivors following resection of adrenocortical carcinoma.

Authors:  Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  J Surg Oncol       Date:  2016-09-16       Impact factor: 3.454

Review 4.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 5.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

Review 6.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

7.  Primary adrenocortical sarcomatoid carcinoma: Report of a case.

Authors:  Jia-Jun Yan; Ai-Jing Sun; Yu Ren; Chuanlin Hou
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

8.  Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma.

Authors:  Javier Valero-Elizondo; Yuhree Kim; Jason D Prescott; Georgios A Margonis; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

9.  Spontaneous rupture of a functioning adrenocortical carcinoma.

Authors:  Jin Ook Chung; Dong Hyeok Cho; Jae Hyuk Lee; Dong Deuk Kwon; Dong Jin Chung; Min Young Chung
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

10.  A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma.

Authors:  Mouhammed Amir Habra; Shamim Ejaz; Lei Feng; Prajnan Das; Ferhat Deniz; Elizabeth G Grubbs; Alexandria Phan; Steven G Waguespack; Montserrat Ayala-Ramirez; Camilo Jimenez; Nancy D Perrier; Jeffrey E Lee; Rena Vassilopoulou-Sellin
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.